Alpha Teknova Q2 2023 Earnings Report

Alpha Teknova EPS Results

• Actual EPS: -$0.25
• Consensus EPS: -$0.26
• Beat/Miss: Beat by +$0.01
• One Year Ago EPS: N/A

Alpha Teknova Revenue Results

• Actual Revenue: $11.53 million
• Expected Revenue: $9.60 million
• Beat/Miss: Beat by +$1.93 million
• YoY Revenue Growth: N/A

Alpha Teknova Announcement Details

• Quarter: Q2 2023
• Date: 8/10/2023
• Time: N/A

Alpha Teknova (NASDAQ:TKNO) produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.